Last Updated: 03/06/2026

RQ Biotechnology

London

Founded 2021

Monoclonal antibodies for viral infectious disease

RQ Biotechnology is a passive immunisation company discovering and developing long-acting monoclonal antibodies to provide immediate protection against viral infections in immunocompromised and vulnerable populations.

Founded by members of the UK COVID-19 Antibody Taskforce and co-founded with LifeArc, the company's pipeline spans influenza, RSV, and CMV.

Its SARS-CoV-2 antibody programme was licensed to AstraZeneca and has progressed through Phase III trials.

Biotech Immunology Infectious Disease

Antibody Therapeutics Vaccines

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of

White City Innovation District BioIndustry Association

Similar Companies